Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al

  1. July 29, 2024

    Boehringer Appeals HHS Win In Medicare Drug Price Suit

    Boehringer Ingelheim Pharmaceuticals Inc. notified a Connecticut federal court Friday that it will appeal its loss in a lawsuit challenging a new Medicare drug price negotiation program on the grounds that it unlawfully compels the pharmaceutical giant to declare prices "fair," takes its property and imposes an excessive fine.

  2. July 03, 2024

    HHS Scores Early Win In Boehringer's Medicare Pricing Suit

    A Connecticut federal judge on Wednesday sided with the U.S. Department of Health and Human Services in Boehringer Ingelheim's challenge to a new Medicare drug price negotiation program, rejecting the pharmaceutical company's claim that the program is unconstitutional.

  3. June 20, 2024

    HHS Drug Pricing Program Flouts Constitution, Boehringer Says

    An "unprecedented" new Medicare price negotiation program deprives drugmakers of their constitutional rights and forces them to make declarations on issues of public concern that reflect poorly on them, Boehringer Ingelheim Pharmaceuticals Inc. argued Thursday in Connecticut federal court as it echoed the industry chorus seeking to strike the initiative.

  4. December 21, 2023

    HHS Seeks Early Win Defending Medicare Drug Price Program

    Boehringer Ingelheim and other drugmakers are free to take their business elsewhere if they object to the new Medicare price negotiation program, the federal government has said, urging a judge to reject the company's claims of constitutional violations.

  5. October 06, 2023

    Mapping Big Pharma's Blitz On Medicare Drug Price Talks

    Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.

  6. September 28, 2023

    Boehringer Bemoans Medicare Drug Price Talks As 'A Sham'

    Boehringer Ingelheim Pharmaceuticals Inc. slammed the new Medicare drug price negotiation program in a Connecticut federal court filing as a "sham from beginning to end," even as it indicated Thursday that it will engage with federal officials.

  7. September 01, 2023

    Novartis Joins Legal Fray After Price Negotiation List Unveiled

    Novartis Pharmaceuticals Corp. on Friday joined the growing list of pharmaceutical companies challenging the Inflation Reduction Act, filing suit in New Jersey federal court just days after the Biden administration revealed the list of drugs in the inaugural round of Medicare price negotiations.

  8. August 21, 2023

    Boehringer Challenges Medicare Drug Price Negotiation Law

    Boehringer Ingelheim Pharmaceuticals Inc. has filed another in a string of constitutional challenges to the Inflation Reduction Act, arguing that the U.S. Department of Health and Human Services is derailing drug research and innovation by taking property without due process protections as part of a scheme to cut drug prices.